Attacking Tumors at the Source

Our technology provides a new opportunity to “drug the undruggable”. We target specific protein-protein interactions, which when disrupted can lead to a “pro-cell death” fate or modulated immune response in targeted cells.

View Our Platform

Enabling Treatments Aimed at Dysregulated PPIs

Our lead candidate, ST101, is a cell-penetrating peptide antagonist of C/EBPβ designed to target various solid tumors (including breast cancer, melanoma, prostate cancer, GBM, lung cancer, and AML) and hematologic malignancies.

In July 2020, we initiated the first clinical trial for ST101, which has also been granted Orphan Drug Designation for the treatment of glioma and AML by the U.S. FDA.

More About ST101

Latest News

Sapience Therapeutics Announces Poster Presentation on ST101 Phase 1 Study Results at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma

Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways

Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs

Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect

Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

Sapience Therapeutics Strengthens Executive Team with Appointments of Marisa Frackman as Chief Financial Officer and Seth I. Rubin as General Counsel

Sapience Therapeutics to Present at Guggenheim Healthcare Talks, 2022 Oncology Conference

Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today